Please join us in welcoming Marcel Bourgeois to #NSPharma as National Director!
With 15+ years in #PatientAccess, including leadership at Takeda, he’s launched programs & teams improving access for rare disease patients. Excited to have you aboard!
We are conducting a Phase 2 #ClinicalTrial evaluating NS-229, an investigational JAK1 inhibitor, to learn more about potential new treatment options for adults with #EGPA.
See if you are eligible to join:
https://clinicaltrials.gov/study/NCT06046222#participation-criteria
At #NSPharma, we’re committed to advancing science & hope for #RareDiseases.
This #HunterSyndromeAwareness Week (Oct 19–25), we stand with families & advocates to raise awareness of #MPSII, a rare genetic disorder that primarily affects boys.